^
Association details:
| Biomarker: | SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dubermatinib (TP-0903) (AXL inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Published date:
12/03/2020
Excerpt:
We also showed that TP-0903 had ex vivo activity in primary AML cells with recurrent mutations including MLL-PTD, ASXL1, SRSF2, and WT1, which are associated with poor prognosis or promote clinical resistance to AML-directed therapies.
DOI:
10.1172/jci.insight.140169
